The diagnostic and therapeutic isotope producer secured series C-5 funding, which will be used to accelerate the development of new fusion-based technology applications.
US-based medical isotopes producer Shine Medical Technologies completed a $150m series C-5 round yesterday led by Koch Disruptive Technologies (KDT), an investment subsidiary of chemicals and energy conglomerate Koch Industries.
The round also featured investment and financial services group Fidelity Management and Research, asset management firm Baillie Gifford and undisclosed other investors.
Founded in 2010, Shine has developed fusion-based technology for the production of diagnostic and therapeutic isotopes, including molybdenum-99, which is used to diagnose heart disease and cancer, and…
